drugset / Trial / NCT06887322

The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions

NCT06887322 ↗

Phase 1/2 Enrolling by invitation 40 enrolled Padjadjaran University
RandomizedParallel-groupOpen-labelTreatment

Summary

Psoriasis vulgaris is a chronic inflammatory skin disease mediated by the immune system, with a complex pathogenesis that requires long-term therapy. Various inflammatory mediators that activate and are produced from the NF-κB signaling pathway play a role in the pathogenesis of psoriasis vulgaris. Topical corticosteroids are the first-line therapy for all severity levels of psoriasis vulgaris, possessing immunosuppressive, anti-inflammatory, and antimitotic effects. However, long-term use can lead to side effects such as atrophy, striae, telangiectasia, hypopigmentation, acneiform eruptions, perioral dermatitis, and hypertrichosis.

Timeline

Start
2025-02-13
Primary completion
2025-04-10
Completion
2025-04-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bethametasone valerate Unknown 0.1 % Topical
Subject Ciplukan Unknown 20 % Topical

Indications